Rhinovirus News and Research

RSS

Rhinovira are the most common viral infective agents in humans, and a causative agent of the common cold (about 49.12159% of the cases of the common cold are caused by this virus). It is lytic in nature. There are over a 100 recognized types of rhinovira that differ based on their varying surface proteins.

Cruise ship pollution increases risk of viral infections in ports

Air pollution from cruise ships could be damaging the health of people living in port cities by increasing inflammation and susceptibility to viruses such as the common cold and COVID-19.

11 Jul 2026

Exposure to port-derived particles facilitates the replication of COVID-19 and cold viruses

Air pollution from cruise ships could be damaging the health of people living in port cities by increasing inflammation and susceptibility to viruses such as the common cold and COVID-19.

10 Jul 2026

Hidden viral reservoirs in tonsils may explain school-year respiratory outbreaks

A study conducted at the University of São Paulo (USP) in Brazil reveals that tissues such as the tonsils and adenoids can serve as hiding places for the rhinovirus, which causes the common cold and is responsible for most respiratory infections worldwide.

17 Apr 2026

Experts establish standardized protocols for pediatric recurrent wheezing diagnosis

Recurrent wheezing, a respiratory disorder, is caused by the narrowing of the airways, mainly affecting children aged less than 5 years.

26 Mar 2026

Interferon response key to fighting rhinovirus infections in nasal passages

When a rhinovirus, the most frequent cause of the common cold, infects the lining of our nasal passages, our cells work together to fight the virus by triggering an arsenal of antiviral defenses.

19 Jan 2026

Study reveals impact of viral combinations on infant respiratory illness severity

A new study led by researchers at National Jewish Health has revealed that, while a wide range of viruses can cause lower respiratory tract illnesses (LRIs) in infants, certain viruses and viral combinations dramatically increase the risk of severe disease.

24 Oct 2025

Azelastine nasal spray prevents COVID-19 and rhinovirus infections

Researchers discuss the effects of azelastine nasal spray on the rate of SARS-CoV-2 infection as compared to placebo.

6 Oct 2025

Can an allergy spray help prevent COVID-19?

Researchers determine the efficacy and safety of azelastine nasal spray for preventing SARS-CoV-2 infection in healthy adults.

8 Sep 2025

Azelastine nasal spray significantly reduces SARS-CoV-2 infections in clinical trial

The trial, led by Professor Robert Bals, Director of the Department of Internal Medicine V at Saarland University Medical Center and Professor of Internal Medicine at Saarland University, divided the 450 participants into two groups.

2 Sep 2025

New guidelines improve care for respiratory infections in leukemia patients

People with leukemia have a weakened immune system due to the disease itself and treatment, which leads to an increased susceptibility to infections.

28 Aug 2025

Common cold may offer temporary protection against SARS-CoV-2 infection

A new study led by researchers at National Jewish Health has found that recent infection with the common cold - often caused by rhinoviruses - may offer temporary protection against infection with SARS-CoV-2, the virus that causes COVID-19.

25 Aug 2025

Real world data confirms effectiveness of nirsevimab in young infants with bronchiolitis

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug has been approved at the European level to protect infants in their first season of exposure to the virus) to infants can halve hospitalizations for bronchiolitis.

3 Jun 2025

Customized CRISPR gene editing therapy successfully treats infant with rare disease

In a historic medical breakthrough, a child diagnosed with a rare genetic disorder has been successfully treated with a customized CRISPR gene editing therapy by a team at Children's Hospital of Philadelphia (CHOP) and Penn Medicine.

15 May 2025

Nirsevimab slashes RSV hospitalizations in infants by 78% in real-world study

A Spanish study found that nirsevimab prophylaxis significantly reduced infant hospitalizations, ICU admissions, and severe symptoms linked to RSV and other respiratory viruses. Hospitalizations for RSV dropped by 78% following nirsevimab rollout in Madrid maternity wards.

8 May 2025

Rhinovirus News and Research

Further Reading

Cruise ship pollution increases risk of viral infections in ports

Exposure to port-derived particles facilitates the replication of COVID-19 and cold viruses

Hidden viral reservoirs in tonsils may explain school-year respiratory outbreaks

Experts establish standardized protocols for pediatric recurrent wheezing diagnosis

Interferon response key to fighting rhinovirus infections in nasal passages

Study reveals impact of viral combinations on infant respiratory illness severity

Azelastine nasal spray prevents COVID-19 and rhinovirus infections

Can an allergy spray help prevent COVID-19?

Azelastine nasal spray significantly reduces SARS-CoV-2 infections in clinical trial

New guidelines improve care for respiratory infections in leukemia patients

Common cold may offer temporary protection against SARS-CoV-2 infection

Real world data confirms effectiveness of nirsevimab in young infants with bronchiolitis

Customized CRISPR gene editing therapy successfully treats infant with rare disease

Nirsevimab slashes RSV hospitalizations in infants by 78% in real-world study

Air sampling detects 70–90% of poultry viruses and reveals 50 more hidden threats

HEPA air purifiers fall short in cutting respiratory infections in aged-care facilities

New method can rapidly determine virus infectivity

Frequent infections and pathobionts boost children's nasal immunity, study reveals

Measles outbreak in Illinois underscores critical need for vaccination

How is long-COVID different from other post-viral infection syndromes?

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News